For the quarter ending 2025-09-30, SILO had -$416,045 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,110,438 | -2,235,730 |
| Amortization expense | 2,938 | 5,565 |
| Net realized (gain) loss on short-term investments | 0 | 3,911 |
| Unrealized loss on crypto assets | -2,690 | - |
| Stock-based compensation | 47,267 | 17,445 |
| Common stock issued for research and development | 518,225 | - |
| Prepaid expenses and other current assets | 56,592 | 79,186 |
| Accounts payable and accrued expenses | -341,558 | -593,700 |
| Deferred revenue | -18,025 | -36,051 |
| Net cash used in operating activities | -955,493 | -2,925,568 |
| Proceeds from the sale of short-term debt investments | 0 | 1,315,653 |
| Purchases of short-term investments | 20,501 | 56,170 |
| Purchases of crypto assets | 74,973 | - |
| Net cash provided by investing activities | -95,474 | 1,259,483 |
| Net proceeds from sale of common stock and pre-funded warrants | 0 | 1,593,897 |
| Purchase of treasury stock | - | 0 |
| Proceeds from exercise of warrants, net of offering costs | 634,922 | 500,061 |
| Net cash provided by financing activities | 634,922 | 2,093,958 |
| Net increase in cash and cash equivalents | -416,045 | 427,873 |
| Cash and cash equivalents at beginning of period | 3,905,799 | - |
| Cash and cash equivalents at end of period | 3,917,627 | - |
Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. (SILO)